1643P - Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Translational Research
Presenter Marcello Tiseo
Citation Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390
Authors M. Tiseo1, F. Facchinetti2, F. Gelsomino2, S. Buti1, M. Veneziani1, A. Squadrilli1, P. Bordi1, M. Bersanelli1, A. Cosenza1, L. Ferri1, E. Rapacchi1, G. Mazzaschi3, F. Leonardi1, F. Quaini3, A. Ardizzoni4, G. Missale5
  • 1Medical Oncology Unit, University Hospital of Parma, 43126 - Parma/IT
  • 2Medical Oncology Unit, University Hospital of Parma, Parma/IT
  • 3Department Of Medicine And Surgery, University Hospital of Parma, 43126 - Parma/IT
  • 4Medical Oncology Unit, University Hospital Sant'Orsola, Bologna/IT
  • 5Malattie Infettive Ed Epatologia, University Hospital of Parma, 43126 - Parma/IT

Abstract

Background

Detection of predictive markers of anti-PD-1/PD-L1 antibodies activity is of pivotal interest in non-small cell lung cancer (NSCLC). This study aimed to identify a circulating immuno-profile as predictor of outcome in NSCLC patients treated with nivolumab.

Methods

A peripheral blood immuno-profile evaluation was performed at baseline (T0), after 2 (T1) and 4 cycles (T2) of bi-weekly nivolumab in advanced pre-treated NSCLC patients from two Italian Institutions. First tumor assessment was performed after 4 cycles and then every 2 months. FACS analysis of lymphocyte subpopulations [CD3, CD4, CD8, NK (CD56), Treg (FOXP3) and MDSC] was performed. Absolute and % changes of lymphocyte subsets together with their functional and proliferative activity were assessed. Quali-quantitative leucocyte composition at baseline and its variation during therapy were correlated with tumor response and survival.

Results

In the overall population of 54 treated patients, baseline Neutrophil-to-Lymphocyte ratio and NK count, lymphocyte count and CD4 variations during therapy showed a statistically significant prognostic role (p 

Conclusions

The number and function of NKs and the frequency of PD-1 expression in CD8+ cells could represent predictive peripheral immuno-biomarkers for nivolumab treatment in advanced NSCLC.

Clinical trial identification

NA

Legal entity responsible for the study

University Hospital of Parma

Funding

AIRC

Disclosure

All authors have declared no conflicts of interest.